

July 15, 2022

Eisai Co., Ltd.

Notification Regarding U.S. Research and Development Subsidiary

The Eisai Group's Corporate Concept is "to give first thought to patients and the people in the daily living domain, and to increase the benefits that health care provides to them". Under this Concept (also known as *human health care (hbc)* Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities.

As a result of a review of the appropriate allocation of resources to further promote drug creation innovation in our R&D division, Eisai has decided to shift to a new R&D structure as of July 15, and to integrate our U.S. R&D subsidiary H3 Biomedicine Inc. (Cambridge, Massachusetts, "H3") into its parent company, Eisai Inc. (Nutley, New Jersey). The merger is scheduled to be completed by the end of this year, and H3's research functions and assets such as drug discovery platform and investigational products will be transferred to the group, and H3's office/laboratory in Cambridge will be closed.